3,9-Diazabicyclo[4.2.1]nonan-4-one | 1210963-09-9

• 物质功能分类: 有机原料 - 酮类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,9-Diazabicyclo[4.2.1]nonan-4-one
• CAS: 1210963-09-9
• 化学式: C₇H₁₂N₂O
• mdl: MFCD12755865
• 分子量: 140.18
• InChiKey: OJDDWFBNQVXOPZ-UHFFFAOYSA-N

物化性质

• 沸点：
  342.0±35.0 °C(Predicted)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6<br/>[FR] COMPOSÉS DE LA PYRROLOPYRIMIDINE UTILISÉS EN TANT QU'INHIBITEURS DES CDK4/6
  申请人：NOVARTIS AG

  公开号：WO2011101409A1

  公开（公告）日：2011-08-25

  The invention is directed to novel pyrrolopyrimidine compounds of formula (I) wherein R1, R2Y, R4, R8- R11, A and L are defined herein and to salts, including pharmaceutically acceptable salts thereof. The compounds of the present invention are CDK4/6 inhibitors and could be useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non small cell lung cancer, melanoma, squamous cell esophageal cancer and breast cancer. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CDK4/6 activity and to the treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及一种新型吡咯吡嘧啶化合物，其化学式为（I），其中R1、R2Y、R4、R8-R11、A和L的定义如下，以及其盐，包括其药用可接受盐。本发明的化合物是CDK4/6抑制剂，可用于治疗由CDK4/6介导的疾病和紊乱，如癌症，包括袍细胞淋巴瘤、脂肪肉瘤、非小细胞肺癌、黑色素瘤、鳞状细胞食管癌和乳腺癌。本发明还涉及包含本发明化合物的药物组合物。此外，本发明还涉及通过使用本发明化合物或包含本发明化合物的药物组合物来抑制CDK4/6活性和治疗相关疾病的方法。
• Substituted bridged-diazabicycloalkyl quinolone carboxylic acids
  申请人：PFIZER INC.

  公开号：EP0215650A2

  公开（公告）日：1987-03-25

  Antibacterial compounds have the formula wherein R1 is hydrogen, a pharmaceutically acceptable cation, or alkyl; A is CH, CF, CCI or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R2 is a bridged-diazabicycloalkyl group.

  抗菌化合物具有如下式子 其中 R1 是氢、药学上可接受的阳离子或烷基；A 是 CH、CF、CCI 或 N；Y 是烷基、卤代烷基、环丙基、乙烯基、甲氧基、N-甲基氨基、对氟苯基、对羟基苯基或对氨基苯基；或 A 是碳，并与 Y 以及 A 和 Y 所连接的碳和氮一起形成任选被取代的五至七位环；R2 是桥联的二氮杂双环烷基。
• [EN] AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS<br/>[FR] DÉRIVÉS D'AZÉPANE ET PROCÉDÉS DE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
  申请人：NOVIRA THERAPEUTICS INC

  公开号：WO2015073774A1

  公开（公告）日：2015-05-21

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.